SEC Tracker
Get the app
RAPH · XBRL financial data

Raphael Pharmaceutical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RAPH's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development510(348)*37924162211*7214173345*3740
General and administrative219214*168225157183*353174178(91)*186159
Operating income (loss)(729)134*(547)(249)(319)(394)*(425)(315)(251)(254)*(223)(199)
Net income (loss)(725)122*(550)(248)(326)(395)*(429)(322)(255)(273)*(229)(223)
Earnings per share, basic USD per share0.040.01*0.030.010.01(0.02)*0.020.020.01(0.01)*0.010.01
Earnings per share, diluted USD per share0.040.01*0.030.010.01(0.02)*0.020.020.01(0.01)*0.010.01
Weighted average shares, basic thousands of shares16,44418,326*18,61718,67618,70118,702*19,62619,62619,62619,330*20,17620,176
Weighted average shares, diluted thousands of shares16,44418,326*18,61718,67618,70118,702*19,62619,62619,62619,330*20,17620,176

Balance sheet

CSV

Fiscal quarters (RAPH's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2992302871204019502034511
Total current assets4023373501264925912855116
Property and equipment, net—2——22222221
Total assets4033393531285127933075337
Accounts payable—69———125———163——
Accrued liabilities—25———375———343——
Total current liabilities478724564186677698271,0781,2711,4861,6651,892
Accumulated deficit(7,432)(7,310)(7,860)(8,108)(8,434)(8,889)(9,318)(9,640)(9,895)(10,168)(10,397)(10,620)
Total stockholders' equity(75)(267)(103)(290)(616)(742)(734)(1,048)(1,264)(1,433)(1,662)(1,885)
Total liabilities and equity4033393531285127933075337
Common shares outstanding (cover page) thousands of shares18,10218,66118,66118,70118,70119,62619,62619,62619,62620,17620,17620,176

Cash flows

CSV

Fiscal quarters (RAPH's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(725)122*(550)(248)(326)(395)*(429)(322)(255)(273)*(229)(223)
Stock-based compensation—year only——0*289*1978*39*1*——
Net cash from operating activities(501)*(88)*(172)(218)*(80)*(62)*(209)(30)*(17)*46*(44)0*
Purchases of property and equipment——1—————————
Net cash from investing activities——(1)—————————
Proceeds from issuing common stock812*19*180100*0*0*2400*0*3*——
Net cash from financing activities689*19*23050*0*41*2400*0*(4)*——
Net change in cash188*(69)*57(167)*(80)*———————

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Raphael Pharmaceutical1not reported0*20.2M— 10-QJun 30, 2026
Bioxytran177not reported(350)*114.7M0.5 quarters 10-QJun 30, 2026
Artelo Biosciences4,198not reported(5,033)*4.6M0.8 quarters 10-QJun 30, 2026
Alaunos Therapeutics1240(300)*2.5M0.4 quarters 10-QJun 30, 2026
BioCardia4,117not reported(1,735)*15.1M2.4 quarters 10-QJun 30, 2026
Oncotelic Therapeutics186250(92)*457.5M2.0 quarters 10-QJun 30, 2026
Traws Pharma5,016not reported(7,504)*15.4M0.7 quarters 10-QJun 30, 2026
TherapeuticsMD9,189not reportednot reported11.6M— 10-QJun 30, 2026
Mannatech6,03426,650(792)*1.9M7.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.